MK4830-001: A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab for Participants With Advanced Solid Tumors

February 19, 2019
https://clinicaltrials.gov/ct2/results?id=NCT03564691
Cancer - Renal Cell
Principal Investigator: Ding Wang, MD
Cancer, Renal Cell, Renal Cancer, Phase 1, Phase I, Neoplasms, Solid Tumors, Advanced, Pembrolizumab, MK4830
Open